20 results on '"Tesař, Vladimír"'
Search Results
2. Challenges in IgA Nephropathy Management: An Era of Complement Inhibition
3. Early Identification of CKD—A Scoping Review of the Global Populations
4. WCN24-1674 NEFECON TREATMENT RESPONSE IN ASIAN AND WHITE PATIENT POPULATIONS WITH IMMUNOGLOBULIN A NEPHROPATHY: A 2YEAR ANALYSIS OF THE PHASE III NEFIGARD TRIAL
5. WCN24-1774 eGFR DECLINE IN PATIENTS WITH IgAN TREATED WITH NEFECON OR PLACEBO: RESULTS FROM THE 2-YEAR NefIgArd PHASE 3 TRIAL
6. WCN24-1776 NEFECON EFFECT ON QUALITY OF LIFE IN PATIENTS WITH IgAN: SF-36 RESULTS FROM THE PHASE 3 NeFIgArd TRIAL
7. WCN24-1777 NEFECON TREATMENT PROVIDES KIDNEY BENEFITS FOR PATIENTS WITH IgAN THAT EXTEND TO THOSE WITH LOW LEVELS OF UPCR: A SUB-ANALYSIS OF THE PHASE III NefIgArd TRIAL
8. Rituximab in Membranous Nephropathy
9. Comparisons of Guidelines and Recommendations on Managing Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
10. International Physicians Delphi Survey: Managing Patients With IgA Nephropathy
11. Diagnosis and Treatment of Patients With Focal Segmental Glomerulosclerosis/Steroid-Resistant Nephrotic Syndrome: A Delphi Survey
12. WCN24-2506 IMMUNOSUPPRESSIVE THERAPY IS NOT ASSOCIATED WITH INCREASED FREQUENCY OF PERITONITIS IN PERITONEAL DIALYSIS PATIENTS – A SINGLE CENTRE EXPERIENCE
13. WCN24-815 THE EFFECTS OF HEMODIALYSIS FISTULA FLOW ON THE RIGHT HEART AND ON PULMONARY HYPERTENSION
14. WCN24-2509 RETROSPECTIVE HISTOPATHOLOGICAL ANALYSIS OF FIBRILLARY GLOMERULONEPHRITIS
15. WCN24-1414 ORIGIN 3: PIVOTAL PHASE 3 STUDY EVALUATING EFFECT OF ATACICEPT VS PLACEBO ON PROTEINURIA AND RENAL FUNCTION PRESERVATION IN IGA NEPHROPATHY
16. WCN24-1294 ATACICEPT REDUCES HEMATURIA AND SERUM GD-IGA1, BOTH ASSOCIATED WITH LONG-TERM RENAL OUTCOMES IN IGA NEPHROPATHY: 36-WEEK RESULTS FROM THE PHASE 2B ORIGIN STUDY
17. WCN24-342 ATACICEPT IN IGA NEPHROPATHY: CONTINUED PROTECTIVE TITERS TO DIPHTHERIA AND TETANUS AND BALANCED INFECTIONS VS PLACEBO WITH A FOCUS ON COVID-19
18. WCN24-871 HIGH-OUTPUT HEART FAILURE AMONG PATIENTS ON CHRONIC HEMODIALYSIS: NOT ONLY DUE TO HIGH FISTULA FLOW
19. ANCA Vasculitis Induction Management During the COVID-19 Pandemic
20. Why Target the Gut to Treat IgA Nephropathy?
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.